The relationship between oxidative stress and nonalcoholic fatty liver disease: Its effects on the development of nonalcoholic steatohepatitis

References

• Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008;28(4):339–50.
   PubMed Web of Science ®Google Scholar
• Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001;121(3):710–23.
   PubMed Web of Science ®Google Scholar
• Day CP, James OFW. Steatohepatitis: a tale of two ‘hits’?. Gastroenterology 1998;114(4):842–5.
   PubMed Web of Science ®Google Scholar
• Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem 2012;23(3):203–8.
   PubMed Web of Science ®Google Scholar
• Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107(5):450–5.
   PubMed Web of Science ®Google Scholar
• Gutteridge JM, Halliwell B. Free radicals and antioxidants in the year 2000. A historical look to the future. Ann N Y Acad Sci 2000;899:136–47.
   PubMed Web of Science ®Google Scholar
• Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001;281(5):G1135–9.
   PubMed Web of Science ®Google Scholar
• Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012;52(1):59–69.
   PubMed Web of Science ®Google Scholar
• Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006;6(1):1–28.
   PubMed Web of Science ®Google Scholar
• Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 2011;412(15–16):1297–305.
   PubMed Web of Science ®Google Scholar
• Bonekamp NA, Völkl A, Fahimi HD, Schrader M. Reactive oxygen species and peroxisomes: struggling for balance. Biofactors 2009;35(4):346–55.
   PubMed Web of Science ®Google Scholar
• Cullinan SB, Diehl JA. Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. Int J Biochem Cell Biol 2006;38(3):317–32.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003;37(3):544–50.
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl) 2009;87(7):679–95.
   PubMed Web of Science ®Google Scholar
• Emery MG, Fisher JM, Chien JY, Kharasch ED, Dellinger EP, Kowdley KV, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003;38(2):428–435.
   PubMed Web of Science ®Google Scholar
• Akyol O, Herken H, Uz E, Fadillioğlu E, Unal S, Söğüt S, et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002;26(5):995–1005.
   PubMed Web of Science ®Google Scholar
• Hardwick RN, Fisher CD, Canet MJ, Lake AD, Cherrington NJ. Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 2010;38(12):2293–301.
   PubMed Web of Science ®Google Scholar
• Yesilova Z, Yaman H, Oktenli C, Ozcan A, Uygun A, Cakir E, et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol 2005;100(4):850–5.
   PubMed Web of Science ®Google Scholar
• Sumida Y, Nakashima T, Yoh T, Furutani M, Hirohama A, Kakisaka Y, et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatol 2003;38(1):32–8.
   Web of Science ®Google Scholar
• Nakashima T, Sumida Y, Furutani M, Hirohama A, Okita M, Mitsuyoshi H, et al. Elevation of serum thioredoxin levels in patients with nonalcoholic steatohepatitis. Hepatol Res 2005;33(2):135–7.
   PubMed Web of Science ®Google Scholar
• Videla LA, Rodrigo R, Araya J, Poniachik J. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med 2006;12(12):555–8.
   PubMed Web of Science ®Google Scholar
• Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, et al. Increase in long-chain polyunsaturated fatty acid n− 6/n−3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004;106(6):635–43.
   PubMed Web of Science ®Google Scholar
• Grattagliano I, de Bari O, Bernardo TC, Oliveira PJ, Wang DQ, Portincasa P. Role of mitochondria in nonalcoholic fatty liver disease–from origin to propagation. Clin Biochem 2012;45(9):610–8.
   PubMed Web of Science ®Google Scholar
• Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005;42(6):928–40.
   PubMed Web of Science ®Google Scholar
• Pérez-Carreras M, Del Hoyo P, Martín MA, Rubio JC, Martín A, Castellano G, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003;38(4):999–1007.
   PubMed Web of Science ®Google Scholar
• Chavin KD, Yang S, Lin HZ, Chatham J, Chacko VP, Hoek JB, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999;274(9):5692–700.
   PubMed Web of Science ®Google Scholar
• Teodoro JS, Rolo AP, Duarte FV, Simões AM, Palmeira CM. Differential alterations in mitochondrial function induced by a choline-deficient diet: understanding fatty liver disease progression. Mitochondrion 2008;8(5–6):367–76.
   PubMed Web of Science ®Google Scholar
• Nakatani T, Tsuboyama-Kasaoka N, Takahashi M, Miura S, Ezaki O. Mechanism for peroxisome proliferator-activated receptor-alpha activator-induced up-regulation of UCP2 mRNA in rodent hepatocytes. J Biol Chem 2002;277(11):9562–9.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120(5):1183–92.
   PubMed Web of Science ®Google Scholar
• Oliveira CP, da Costa Gayotto LC, Tatai C, Della Bina BI, Janiszewski M, Lima ES, et al. Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet. J Cell Mol Med 2002;6(3):399–406.
   PubMed Web of Science ®Google Scholar
• Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009;41(9):615–25.
   PubMedGoogle Scholar
• Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 1995;96(5):2461–8.
   PubMed Web of Science ®Google Scholar
• Armutcu F, Coskun O, Gürel A, Kanter M, Can M, Ucar F, et al. Thymosin alpha 1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats. Clin Biochem 2005;38(6):540–7.
   PubMed Web of Science ®Google Scholar
• Uysal S, Armutcu F, Aydogan T, Akin K, Ikizek M, Yigitoglu MR. Some inflammatory cytokine levels, iron metabolism and oxidan stress markers in subjects with nonalcoholic steatohepatitis. Clin Biochem 2011;44(17–18):1375–9.
   PubMed Web of Science ®Google Scholar
• Rabelo F, Oliveira CP, Faintuch J, Mazo DF, Lima VM, Stefano JT, et al. Pro- and anti-inflammatory cytokines in steatosis and steatohepatitis. Obes Surg 2010;20(7):906–12.
   PubMed Web of Science ®Google Scholar
• Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008;103(6):1372–9.
   PubMed Web of Science ®Google Scholar
• Estep JM, Baranova A, Hossain N, Elariny H, Ankrah K, Afendy A, et al. Expression of cytokine signaling genes in morbidly obese patients with non-alcoholic steatohepatitis and hepatic fibrosis. Obes Surg 2009;19(5):617–24.
   PubMed Web of Science ®Google Scholar
• Syn WK, Choi SS, Diehl AM. Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin Liver Dis 2009;13(4):565–80.
   PubMed Web of Science ®Google Scholar
• Diehl AM. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol 2002;282(1):G1–5.
   PubMed Web of Science ®Google Scholar
• Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003;125(2):437–43.
   PubMed Web of Science ®Google Scholar
• Fujita N, Takei Y. Iron Overload in Nonalcoholic Steatohepatitis. Adv Clin Chem 2011;55:105–32.
   PubMed Web of Science ®Google Scholar
• Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002;37(1):56–62.
   PubMed Web of Science ®Google Scholar
• Nomoto K, Tsuneyama K, Takahashi H, Murai Y, Takano Y. Cytoplasmic fine granular expression of 8-hydroxydeoxyguanosine reflects early mitochondrial oxidative DNA damage in nonalcoholic fatty liver disease. Appl Immunohistochem Mol Morphol 2008;16(1):71–5.
   PubMedGoogle Scholar
• Nagakawa Y, Williams GM, Zheng Q, Tsuchida A, Aoki T, Montgomery RA, et al. Oxidative mitochondrial DNA damage and deletion in hepatocytes of rejecting liver allografts in rats: role of TNF-alpha. Hepatology 2005;42(1):208–15.
   PubMed Web of Science ®Google Scholar
• Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30(6):1356–62.
   PubMed Web of Science ®Google Scholar
• Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999;117(5):1155–63.
   PubMed Web of Science ®Google Scholar
• Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 2011;55(4):920–32.
   PubMed Web of Science ®Google Scholar
• George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114(2):311–31.
   PubMed Web of Science ®Google Scholar
• Sumida Y, Yoshikawa T, Okanoue T. Role of hepatic iron in non-alcoholic steatohepatitis. Hepatol Res 2009;39(3):213–22.
   PubMed Web of Science ®Google Scholar
• Fujita N, Miyachi H, Tanaka H, Takeo M, Nakagawa N, Kobayashi Y, et al. Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis. Cancer Epidemiol Biomarkers Prev 2009;18(2):424–32.
   PubMed Web of Science ®Google Scholar
• Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res 2012;2012:145754.
   PubMedGoogle Scholar
• Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D, et al. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technol Assess 2011;15(38):1–110.
   PubMed Web of Science ®Google Scholar
• Haukeland JW, Damås JK, Konopski Z, Løberg EM, Haaland T, Goverud I, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006;44(6):1167–74.
   PubMed Web of Science ®Google Scholar
• Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE, et al. Biomarkers of oxidative stress study II. Are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med 2005;38(6):698–710.
   PubMed Web of Science ®Google Scholar
• Ibrahim MA, Kelleni M, Geddawy A. Nonalcoholic fatty liver disease: current and potential therapies. Life Sci 2013;92(2):114–8.
   PubMed Web of Science ®Google Scholar
• Videla LA, Rodrigo R, Araya J, Poniachik J. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med 2004;37(9):1499–507.
   PubMed Web of Science ®Google Scholar
• Angulo P. NAFLD, obesity, and bariatric surgery. Gastroenterology 2006;130(6):1848.
   PubMed Web of Science ®Google Scholar